>
8 Malignant disease and immunosuppression >
8.1 Cytotoxic drugs >
8.1.5 Other antineoplastic drugs >
Ibrutinib for treating relapsed or refractory mantle cell lymphoma - NICE TAG TA502 - Homepage
-
Formulary Home
-
1 Gastro-intestinal system
- 1.1 Dyspepsia and gastro-oesophageal reflux disease
- 1.2 Antispasmodics and other drugs altering gut motility
- 1.3 Antisecretory drugs and mucosal protectants
- 1.4 Acute diarrhoea
-
1.5 Chronic bowel disorders
- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids
-
1.5.3 Drugs affecting the immune response
- Ulcerative colitis (acute exacerbations) - infliximab - NICE TAG TA163
- Crohn's disease - infliximab (review) and adalimumab (review of TA40) - NICE TAG TA187
- Ulcerative colitis (subacute manifestations) - infliximab - NICE TAG TA140
- Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) - NICE TAG TA329
- Vedolizumab for treating moderately to severely active ulcerative colitis - NICE TAG TA342
- Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy - NICE TAG TA352
- Tofacitinib for moderately to severely active ulcerative colitis - NICE TAG TA547
- 1.5.4 Food allergy
- 1.6 Laxatives
- 1.7 Local preparations for anal and rectal disorders
- 1.8 Stoma care
- 1.9 Drugs affecting intestinal secretions
-
2 Cardiovascular system
- 2.1 Positive inotropic drugs
- 2.2 Diuretics
- 2.3 Anti-arrhythmic drugs
- 2.4 Beta-adrenoceptor blocking drugs
- 2.5 Hypertension and heart failure
- 2.6 Nitrates, calcium-channel blockers, and other antianginal drugs
- 2.7 Sympathomimetics
-
2.8 Anticoagulants and protamine
- 2.8.1 Parenteral anticoagulants
-
2.8.2 Oral anticoagulants
- Atrial fibrillation - dabigatran etexilate - NICE TAG TA249
- Atrial fibrillation (stroke prevention) - rivaroxaban - NICE TAG TA256
- Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban - NICE TAG TA287
- Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban - NICE TAG TA275
- Venous thromboembolism - dabigatran - NICE TAG TA157
- Venous thromboembolism (hip and knee surgery) - apixaban - NICE TAG TA245
- Venous thromboembolism - rivaroxaban - NICE TAG TA170
- Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban - NICE TAG TA261
- Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism - NICE TAG TA327
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome - NICE TAG TA335
- Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism - NICE TAG TA341
- Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation - NICE TAG TA355
- Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism - NICE TAG TA354
- 2.8.3 Protamine sulfate
-
2.9 Antiplatelet drugs
- Acute coronary syndrome - prasugrel - NICE TAG TA182
- Vascular disease - clopidogrel and dipyridamole - NICE TAG TA210
- Acute coronary syndromes - ticagrelor - NICE TAG TA236
- Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) - NICE TAG TA317
- Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) - NICE TAG TA351
- Ticagrelor for preventing atherothrombotic events after myocardial infarction - NICE TAG TA420
- 2.10 Stable angina, acute coronary syndromes, and fibrinolysis
- 2.11 Antifibrinolytic drugs and haemostatics
-
2.12 Lipid-regulating drugs
- Cardiovascular disease - statins - NICE TAG TA94
- Hypercholesterolaemia - ezetimibe - NICE TAG TA132
- Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia - NICE TAG TA385
- Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia - NICE TAG TA385
- Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia - NICE TAG TA394
- Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia - NICE TAG TA393
- 2.13 Local sclerosants
- 2.14 Other cardiovascular drugs
-
3 Respiratory system
- 3.1 Bronchodilators
- 3.2 Corticosteroids
- 3.3 Cromoglicate and related therapy, leukotriene receptor antagonists, and phosphodiesterase type-4 inhibitors
-
3.4 Antihistamines, hyposensitisation, and allergic emergencies
- 3.4.1 Antihistamines
-
3.4.2 Allergen immunotherapy
- Venom anaphylaxis - immunotherapy pharmalgen - NICE TAG TA246
- Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) - NICE TAG TA278
- Omalizumab for previously treated chronic spontaneous urticaria - NICE TAG TA339
- Mepolizumab for treating severe refractory eosinophilic asthma - NICE TAG TA431
- Reslizumab for treating severe eosinophilic asthma - NICE TAG TA479
- Benralizumab for treating severe eosinophilic asthma - NICE TAG TA565
- 3.4.3 Allergic emergencies
- 3.5 Respiratory stimulants and pulmonary surfactants
- 3.6 Oxygen
- 3.7 Mucolytics
- 3.8 Aromatic inhalations
- 3.9 Cough preparations
- 3.10 Systemic nasal decongestants
- 3.11 Antifibrotics
- 3.12 Miscellaneous
-
4 Central nervous system
- 4.1 Hypnotics and anxiolytics
- 4.2 Drugs used in psychoses and related disorders
- 4.3 Antidepressant drugs
- 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
- 4.5 Drugs used in the treatment of obesity
- 4.6 Drugs used in nausea and vertigo
- 4.7 Analgesics
- 4.8 Antiepileptic drugs
- 4.9 Drugs used in parkinsonism and related disorders
- 4.10 Drugs used in substance dependence
- 4.11 Drugs for dementia
-
5 Infections
-
5.1 Antibacterial drugs
- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, carbapenems, and other beta-lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other antibacterials
- 5.1.8 Sulfonamides and trimethoprim
- 5.1.9 Antituberculosis drugs
- 5.1.10 Antileprotic drugs
- 5.1.11 Metronidazole and tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract infections
- 5.2 Antifungal drugs
-
5.3 Antiviral drugs
- 5.3.1 HIV infection
- 5.3.2 Herpesvirus infections
-
5.3.3 Viral hepatitis
- 5.3.3.1 Chronic hepatitis B
-
5.3.3.2 Chronic hepatitis C
- Hepatitis C - peginterferon alfa and ribavirin - NICE TAG TA200
- Hepatitis C (genotype 1) - telaprevir - NICE TAG TA252
- Hepatitis C (genotype 1) - boceprevir - NICE TAG TA253
- Glecaprevir–pibrentasvir for treating chronic hepatitis C - NICE TAG TA499
- Hepatitis C (children and young people) - peginterferon alfa and ribavirin NICE TAG TA300
- Sofosbuvir for treating chronic hepatitis C - NICE TAG TA330
- Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis - NICE TAG TA331
- Ledipasvir–sofosbuvir for treating chronic hepatitis C - NICE TAG TA363
- Daclatasvir for treating chronic hepatitis C - NICE TAG TA364
- Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C - NICE TAG TA365
- Elbasvir–grazoprevir for treating chronic hepatitis C - NICE TAG TA413
- Sofosbuvir–velpatasvir for treating chronic hepatitis C - NICE TAG TA430
- Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C - NICE TAG TA507
- 5.3.4 Influenza
- 5.3.5 Respiratory syncytial virus
- 5.4 Antiprotozoal drugs
- 5.5 Anthelmintics
-
5.1 Antibacterial drugs
-
6 Endocrine system
-
6.1 Drugs used in diabetes
- 6.1.1 Insulins
-
6.1.2 Antidiabetic drugs
- Type 2 diabetes in adults: management - NICE NG28
- Dapagliflozin in combination therapy for treating type 2 diabetes - NICE TAG TA288
- Canagliflozin in combination therapy for treating type 2 diabetes - NICE TAG TA315
- Empagliflozin in combination therapy for treating type 2 diabetes - NICE TAG TA336
- Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes - NICE TAG TA390
- Dapagliflozin in triple therapy for treating type 2 diabetes - NICE TAG TA418
- Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes - NICE TAG TA572
- Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes - NICE TAG TA583
- 6.1.3 Diabetic ketoacidosis
- 6.1.4 Treatment of hypoglycaemia
- 6.1.5 Treatment of diabetic nephropathy and neuropathy
- 6.1.6 Diagnostic and monitoring devices for diabetes mellitus
- 6.2 Thyroid and antithyroid drugs
- 6.3 Corticosteroids
- 6.4 Sex hormones
- 6.5 Hypothalamic and pituitary hormones and anti-oestrogens
-
6.6 Drugs affecting bone metabolism
- 6.6.1 Calcitonin and parathyroid hormone
-
6.6.2 Bisphosphonates and other drugs affecting bone metabolism
- Osteoporosis - primary prevention - NICE TAG TA160
- Osteoporosis - secondary prevention including strontium ranelate - NICE TAG TA161
- Osteoporotic fractures - denosumab - NICE TAG TA204
- Bone metastases from solid tumours – denosumab - NICE TAG TA265
- Bisphosphonates for treating osteoporosis - NICE TAG TA464
- Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) - NICE TAG TA549
- 6.7 Other endocrine drugs
-
6.1 Drugs used in diabetes
-
7 Obstetrics, gynaecology, and urinary-tract disorders
- 7.1 Drugs used in obstetrics
- 7.2 Treatment of vaginal and vulval conditions
- 7.3 Contraceptives
- 7.4 Drugs for genito-urinary disorders
-
8 Malignant disease and immunosuppression
-
8.1 Cytotoxic drugs
- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines and other cytotoxic antibiotics
-
8.1.3 Antimetabolites
- Pancreatic cancer - gemcitabine - Nice TAG TA25
- Leukaemia (lymphocytic) - fludarabine - NICE TAG TA29
- Colorectal cancer - capecitabine and tegafur uracil - NICE TAG TA61
- Renal transplantation - immuno-suppressive regimens (adults) - NICE TAG TA85
- Colon cancer (adjuvant) - capecitabine and oxaliplatin - NICE TAG TA100
- Breast cancer - gemcitabine - NICE TAG TA116
- Leukaemia (lymphocytic) - fludarabine - NICE TAG TA119
- Lung cancer (non-small-cell) - pemetrexed - NICE TAG TA124
- Mesothelioma - pemetrexed disodium NICE TAG TA135
- Lung cancer (non-small-cell, first line treatment) - pemetrexed - NICE TAG TA181
- Lung cancer (non-small-cell) - pemetrexed (maintenance) - NICE TAG TA190
- Gastric cancer (advanced) - capecitabine - NICE TAG TA191
- Myelodysplastic syndromes - azacitidine - NICE TAG TA218
- Lung cancer (non small cell, non squamous) - pemetrexed NICE TAG TA309
- Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin - NICE TAG TA402
- Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts - NICE TAG TA399
- Cladribine tablets for treating relapsing–remitting multiple sclerosis - NICE TAG TA493
- Decitabine for untreated acute myeloid leukaemia (terminated appraisal) - NICE TAG TA548
- 8.1.4 Vinca alkaloids and etoposide
-
8.1.5 Other antineoplastic drugs
- Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) - NICE TAG TA23
- Breast cancer - trastuzumab - NICE TAG TA34
- Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block- NICE TAG TA55
- Gastrointestinal stromal tumours - imatinib - NICE TAG TA86
- Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) - NICE TAG TA91
- Prostate cancer (hormone-refractory) - docetaxel - NICE TAG TA101
- Breast cancer (early) - trastuzumab - NICE TAG TA107
- Breast cancer (early) - paclitaxel - NICE TAG TA108
- Breast cancer (early) - docetaxel - NICE TAG TA109
- Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer- NICE TAG TA118
- Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide - NICE TAG TA121
- Multiple myeloma - bortezomib - NICE TAG TA129
- Head and neck cancer - cetuximab - NICE TAG TA145
- Lung cancer (non-small-cell) - erlotinib - NICE TAG TA162
- Renal cell carcinoma - sunitinib - NICE TAG TA169
- Head and neck cancer (squamous cell carcinoma) - cetuximab - NICE TAG TA172
- Colorectal cancer (first line) - cetuximab - NICE TAG TA176
- Renal cell carcinoma - NICE TAG TA178
- Gastrointestinal stromal tumours - sunitinib - NICE TAG TA179
- Cervical cancer (recurrent) - topotecan - NICE TAG TA183
- Lung cancer (small-cell) - topotecan - NICE TAG TA184
- Soft tissue sarcoma - trabectedin - NICE TAG TA185
- Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) - NICE TAG TA189
- Lung cancer (non-small-cell, first line) - gefitinib - NICE TAG TA192
- Gastrointestinal stromal tumours - imatinib (adjuvant) - NICE TAG TA196
- Gastric cancer (HER2-positive metastatic) - trastuzumab - NICE TAG TA208
- Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib - NICE TAG TA209
- Colorectal cancer (metastatic) - bevacizumab - NICE TAG TA212
- Breast cancer - bevacizumab (in combination with a taxane) - NICE TAG TA214
- Pazopanib for the first-line treatment of advanced renal cell carcinoma - NICE TAG TA215
- Everolimus for the second-line treatment of advanced renal cell carcinoma - NICE TAG TA219
- Ovarian cancer (relapsed) - trabectedin - NIE TAG TA222
- Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) - NICE TAG TA227
- Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228
- Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) - NICE TAG TA241
- Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab - NICE TAG TA242
- Breast cancer (advanced) - eribulin - NICE TAG TA250
- Leukaemia (chronic myeloid, first line) - dasatanib, nilotinib and standard-dose imatinib - NICE TAG TA251
- Prostate cancer - cabazitazel - NICE TAG TA255
- Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) - NICE TAG TA257
- Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) - NICE TAG TA258
- Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer - NICE TAG TA263
- Melanoma (stage III or IV) - ipilimumab - NICE TAG TA268
- Melanoma (BRAF V600 mutation positive, unresectable metastatic) – vemurafenib - NICE TAG TA269
- Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer - NICE TAG TA284
- Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab - NICE TAG TA285
- Myelofibrosis (splenomegaly, symptoms) - ruxolitinib - NICE TAG TA289
- Guidance on the use of imatinib for chronic myeloid leukaemia - NICE TAG TA70
- Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) - NICE TAG TA295
- Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib NICE TAG TA296
- Leukaemia (chronic myeloid) - bosutinib NICE TAG TA299
- Macular oedema (central retinal vein occlusion) - aflibercept solution for injection NICE TAG TA305
- Colorectal cancer (metastatic) - aflibercept NICE TAG TA307
- Lung cancer (non small cell, EGFR mutation positive) - afatinib NICE TAG TA310
- Multiple myeloma - bortezomib (induction therapy) NICE TAG TA311
- Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma - NICE TAG TA319
- Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma - NICE TAG TA321
- Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) - NICE TAG TA326
- Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment - NICE TAG TA333
- Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG TA357
- Ruxolitinib for treating polycythaemia vera (terminated appraisal) - NICE TAG 356
- Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) - NICE TAG TA353
- Aflibercept for treating diabetic macular oedema - NICE TAG TA346
- Everolimus for preventing organ rejection in liver transplantation - NICE TAG TA348
- Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer - NICE TAG TA347
- Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) - NICE TAG TA334
- Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) - NICE TAG TA328
- Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG 357
- Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) - NICE TAG TA362
- Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer - NICE TAG TA360
- Idelalisib for treating chronic lymphocytic leukaemia - NICE TAG TA359
- Pembrolizumab for advanced melanoma not previously treated with ipilimumab - NICE TAG TA366
- Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane - NICE TAG TA371
- Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy - NICE TAG TA374
- Bortezomib for previously untreated mantle cell lymphoma - NICE TAG TA370
- Nintedanib for treating idiopathic pulmonary fibrosis - NICE TAG TA379
- Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy - NICE TAG TA378
- Panobinostat for treating multiple myeloma after at least 2 previous treatments - NICE TAG TA380
- Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy - NICE TAG TA381
- Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis - NICE TAG TA386
- Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer - NICE TAG TA389
- Nivolumab for treating advanced (unresectable or metastatic) melanoma - NICE TAG TA384
- Bosutinib for previously treated chronic myeloid leukaemia - NICE TAG TA401
- Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer - NICE TAG TA403
- Nivolumab in combination with ipilimumab for treating advanced melanoma - NICE TAG TA400
- Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma - NICE TAG TA396
- Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel - NICE TAG TA391
- Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer - NICE TAG TA395
- Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA406
- Pegaspargase for treating acute lymphoblastic leukaemia - NICE TAG TA408
- Talimogene laherparepvec for treating unresectable metastatic melanoma - NICE TAG TA410
- Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer - NICE TAG TA411
- Trifluridine–tipiracil for previously treated metastatic colorectal cancer - NICE TAG TA405
- Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA414
- Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer - NICE TAG TA416
- Nivolumab for previously treated advanced renal cell carcinoma - NICE TAG TA417
- Everolimus with exemestane for treating advanced breast cancer after endocrine therapy - NICE TAG TA421
- Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA422
- Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens - NICE TAG TA423
- Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer - NICE TAG TA424
- Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia - NICE TAG TA425
- Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia - NICE TAG TA426
- Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy- NICE TAG TA428
- Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
- Cetuximab and panitumumab for previously untreated metastatic colorectal cancer - NICE TAG TA439
- Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - NICE TAG TA429
- Everolimus for advanced renal cell carcinoma after previous treatment - NICE TAG TA432
- Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462
- Carfilzomib for previously treated multiple myeloma - NICE TAG TA457
- Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane - NICE TAG TA458
- Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) - NICE TAG TA452
- Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) - NICE TAG TA453
- Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) - NICE TAG TA453
- Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA446
- Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA447
- Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease - NICE TAG TA449
- Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia - NICE TAG451
- Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA444
- Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
- Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
- Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
- Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) - NICE TAG TA469
- Cabozantinib for previously treated advanced renal cell carcinoma - NICE TAG TA463
- Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer - NICE TAG TA476
- Sorafenib for treating advanced hepatocellular carcinoma - NICE TAG TA474
- Ibrutinib for treating Waldenstrom’s macroglobulinaemia - NICE TAG TA491
- Vismodegib for treating basal cell carcinoma - NICE TAG TA489
- Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours - NICE TAG TA488
- Venetoclax for treating chronic lymphocytic leukaemia - NICE TAG TA487
- Ibrutinib for treating relapsed or refractory mantle cell lymphoma - NICE TAG TA502
- Ceritinib for untreated ALK-positive non-small-cell lung cancer - NICE TAG TA500
- Lenvatinib with everolimus for previously treated advanced renal cell carcinoma - NICE TAG TA498
- Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma - NICE TAG TA505
- Cabozantinib for treating medullary thyroid cancer - NICE TAG TA516
- Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen - NICE TAG TA515
- Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA514
- Daratumumab monotherapy for treating relapsed and refractory multiple myeloma - NICE TAG TA510
- Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer - NICE TAG TA509
- Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA519
- Avelumab for treating metastatic Merkel cell carcinoma - NICE TAG TA517
- Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy - NICE TAG TA520
- Arsenic trioxide for treating acute promyelocytic leukaemia - NICE TAG TA526
- Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA525
- Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA524
- Midostaurin for untreated acute myeloid leukaemia - NICE TAG TA523
- Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - NICE TAG TA522
- Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA531
- Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy - NICE TAG TA530
- Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer - NICE TAG TA529
- Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer - NIE TAG TA528
- Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours - NICE TAG TA539
- Dinutuximab beta for treating neuroblastoma - NICE TAG TA538
- Alectinib for untreated ALK-positive advanced non-small-cell lung cancer - NICE TAG TA536
- Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
- Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia - NICE TAG TA541
- Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
- Cabozantinib for untreated advanced renal cell carcinoma - NICE TAG TA542
- Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma - NICE TAG TA544
- Gemtuzumab ozogamicin for untreated acute myeloid leukaemia - NICE TAG TA545
- Vandetanib for treating medullary thyroid cancer - NICE TAG TA550
- Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer - NICE TAG TA557
- Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA555
- Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence - NICE TAG TA553
- Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years - NICE TAG TA554
- Lenvatinib for untreated advanced hepatocellular carcinoma - NICE TAG TA551
- Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
- Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) - NICE TAG TA 564
- Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA563
- Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA562
- Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia - NICE TAG TA561
- Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
- Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib - NICE TAG TA571
- Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA570
- Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer - NICE TAG TA569
- Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TAG TA567
- Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TA TAG567
- Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma - NICE TAG TA577
- Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) - NICE TAG TA576
- Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma - NICE TAG TA573
- Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) - NICE TAG TA582
- Nivolumab with ipilimumab for untreated advanced renal cell carcinoma - NICE TAG TA581
- Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy - NICE TAG TA579
- Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation - NICE TAG TA578
- Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer - NICE TAG TA584
-
8.2 Drugs affecting the immune response
- 8.2.1 Antiproliferative immunosuppressants
-
8.2.2 Corticosteroids and other immunosuppressants
- Renal transplantation - immuno-suppressive regimens (adults) - NICE TAG TA85
- Renal transplantation - immunosuppressive regimens for children and adolescents - NICE TAG TA99
- Daclizumab for treating relapsing–remitting multiple sclerosis - NICE TAG TA441
- Immunosuppressive therapy for kidney transplant in children and young people - NICE TAG TA482
- Immunosuppressive therapy for kidney transplant in adults - NICE TAG TA481
- Ocrelizumab for treating relapsing–remitting multiple sclerosis - NICE TAG TA533
- Ocrelizumab for treating primary progressive multiple sclerosis - NICE TAG TA585
-
8.2.3 Anti-lymphocyte monoclonal antibodies
- Non-Hodgkin's lymphoma - rituximab - NICE TAG TA65
- Lymphoma (follicular non-Hodgkin's) - rituximab NICE TAG TA137
- Leukaemia (chronic lymphocytic, first line) - rituximab - NICE TAG TA174
- Leukaemia (chronic lymphocytic, relapsed) - rituximab - NICE TAG TA193
- Chronic lymphocytic leukaemia - ofatumumab - NICE TAG TA202
- Lymphoma (follicular non-Hodgkin's) - rituximab - NICE TAG TA226
- Follicular lymphoma - rituximab - NICE TAG TA243
- Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) NICE TAG TA308
- Multiple sclerosis (relapsing-remitting) - alemtuzumab NICE TAG TA312
- Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia - NICE TAG TA344
- Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia - NICE TAG TA343
- Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia - TA450
- Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck - NICE TAG TA473
- Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab - NICE TAG TA472
- Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) - NICE TAG TA470
- Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma - NICE TAG TA465
- Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma - NIE TAG TA478
- Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - NICE TAG TA492
- Obinutuzumab for untreated advanced follicular lymphoma - NICE TAG TA513
- Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity - NICE TAG TA589
-
8.2.4 Other immunomodulating drugs
- Multiple sclerosis - beta interferon and glatiramer acetate - NICE TAG TA32
- Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases - NICE TAG TA412
- Hepatitis C - pegylated interferons, ribavirin and alfa interferon - NICE TAG TA75
- Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a - NICE TAG TA96
- Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C - NICE TAG TA106
- Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases - NICE TAG TA376
- Multiple sclerosis - natalizumab - NICE TAG TA127
- Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy - NICE TAG TA171
- Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228
- Osteosarcoma - mifamurtide - NICE TAG TA235
- Multiple sclerosis (relapsing-remitting) - fingolimod - NICE TAG TA254
- Multiple sclerosis (relapsing) - teriflunomide NICE TAG TA303
- Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis - NICE TAG TA320
- Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality - NICE TAG TA322
- Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib - NICE TAG TA338
- Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib - NICE TAG TA427
- Dimethyl fumarate for treating moderate to severe plaque psoriasis - TAG TA475
- Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy - NICE TAG TA490
- Nivolumab for previously treated non-squamous non-small-cell lung cancer - NICE TAG TA484
- Nivolumab for previously treated squamous non-small-cell lung cancer - NICE TAG TA483
- Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462
- Intrabeam radiotherapy system for adjuvant treatment of early breast cancer - NICE TAG TA501
- Tivozanib for treating advanced renal cell carcinoma - NICE TAG TA512
- Beta interferons and glatiramer acetate for treating multiple sclerosis - NICE TAG TA527
- Padeliporfin for untreated localised prostate cancer - NICE TAG TA546
- Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease - NICE TAG TA558
- Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies - NICE TAG TA559
- Lenalidomide plus dexamethasone for previously untreated multiple myeloma - NICE TAG TA587
-
8.3 Sex hormones and hormone antagonists in malignant disease
- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
-
8.3.4 Hormone antagonists
- 8.3.4.1 Breast Cancer
-
8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists
- Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen- NICE TAG TA259
- Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen - NICE TAG TA316
- Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA377
- Degarelix for treating advanced hormone-dependent prostate cancer - NICE TAG TA404
- Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA387
- Enzalutamide for hormone-relapsed non-metastatic prostate cancer - NICE TAG TA580
- 8.3.4.3 Somatostatin analogues
-
8.1 Cytotoxic drugs
-
9 Nutrition and blood
-
9.1 Anaemias and some other blood disorders
- 9.1.1 Iron-deficiency anaemias
- 9.1.2 Drugs used in megaloblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias
-
9.1.4 Drugs used in platelet disorders
- Thrombocytopenic purpura - eltrombopag - NICE TAG TA205
- Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura - NICE TAG TA221
- Thrombocytopenic purpura - eltrombopag - NICE TAG TA293
- Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) - NICE TAG TA382
- 9.1.5 G6PD deficiency
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells
- 9.2 Fluids and electrolytes
- 9.3 Intravenous nutrition
- 9.4 Oral nutrition
- 9.5 Minerals
- 9.6 Vitamins
- 9.7 Bitters and tonics
- 9.8 Metabolic disorders
-
9.1 Anaemias and some other blood disorders
-
10 Musculoskeletal and joint diseases
-
10.1 Drugs used in rheumatic diseases and gout
- 10.1.1 Non-steroidal anti-inflammatory drugs
- 10.1.2 Corticosteroids
-
10.1.3 Drugs that suppress the rheumatic disease process
- Arthritis (juvenile idiopathic) - etanercept - NICE TAG TA35
- Rheumatoid arthritis - adalimumab, etanercept and infliximab - NICE TAG TA130
- Ankylosing spondylitis - adalimumab, etanercept and infliximab- NICE TAG TA143
- Rheumatoid arthritis - certolizumab pegol - NICE TAG TA186
- Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor - NICE TAG TA195
- Psoriatic arthritis - etanercept, infliximab and adalimumab - NICE TAG TA199
- Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG445
- Psoriatic arthritis - golimumab - NICE TAG TA220
- Rheumatoid arthritis (after failure of previous anti-rheumatic drugs) - golimumab - NICE TAG TA225
- Ankylosing spondylitis - golimumab - NICE TAG TA233
- Arthritis (juvenile idiopathic, systemic) - tocilizumab - NICE TAG TA238
- Rheumatoid arthritis - tocilizumab - NICE TAG TA247
- Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) - NICE TAG TA280
- Psoriatic arthritis (active) - ustekinumab NICE TAG TA313
- Apremilast for treating active psoriatic arthritis - NICE TAG TA372
- Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis - NICE TAG TA373
- Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed - NICE TAG TA375
- TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis - NICE TAG TA 383
- Belimumab for treating active autoantibody-positive systemic lupus erythematosus - NICE TAG TA397
- Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors - NICE TAG TA407
- Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor - NICE TAG TA415
- Apremilast for treating active psoriatic arthritis - NICE TAG TA433
- Ustekinumab for moderately to severely active Crohn’s disease after previous treatment - NICE TAG TA456
- Baricitinib for moderate to severe rheumatoid arthritis - NICE TAG TA466
- Tofacitinib for moderate to severe rheumatoid arthritis - NICE TAG TA480
- Sarilumab for moderate to severe rheumatoid arthritis - NICE TAG TA485
- Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA496
- Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA495
- Golimumab for treating non-radiographic axial spondyloarthritis - NICE TAG TA497
- Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee - NICE TAG TA508
- Tocilizumab for treating giant cell arteritis - NICE TAG TA518
- Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG TA543
- Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) - NICE TAG TA568
- Tildrakizumab for treating moderate to severe plaque psoriasis - NICE TAG TA575
- Certolizumab pegol for treating moderate to severe plaque psoriasis - NICE TAG TA574
- 10.1.4 Gout and cytotoxic-induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases
- 10.2 Drugs used in neuromuscular disorders
- 10.3 Drugs for the treatment of soft-tissue disorders and topical pain relief
- Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee - NICE TAG TA477
-
10.1 Drugs used in rheumatic diseases and gout
-
11 Eye
- 11.1 Administration of drugs to the eye
- 11.2 Control of microbial contamination
- 11.3 Anti-infective eye preparations
-
11.4 Corticosteroids and other anti-inflammatory preparations
-
11.4.1 Corticosteroids
- Macular oedema (retinal vein occlusion) - dexamethasone - NICE TAG TA229
- Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) NICE TAG TA301
- Dexamethasone intravitreal implant for treating diabetic macular oedema - NICE TAG TA349
- Cenegermin for treating neurotrophic keratitis - NICE TAG TA532
- Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis - NICE TAG TA590
- 11.4.2 Other anti-inflammatory preparations
-
11.4.1 Corticosteroids
- 11.5 Mydriatics and cycloplegics
- 11.6 Treatment of glaucoma
- 11.7 Local anaesthetics
-
11.8 Miscellaneous ophthalmic preparations
- 11.8.1 Tear deficiency, ocular lubricants, and astringents
-
11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment
- Macular degeneration (age-related) - photodynamic therapy - NICE TAG TA68
- Holoclar for treating limbal stem cell deficiency after eye burns - NICE TAG TA467
- Ranibizumab and pegaptanib for the treatment of age-related macular degeneration - NICE TAG TA155
- Aflibercept for treating choroidal neovascularisation - NICE TAG TA486
- Macular oedema (diabetic) - ranibizumab - NICE TAG TA274
- Macular oedema (retinal vein occlusion) - ranibizumab - NICE TAG TA283
- Macular degeneration (wet age-related) - aflibercept (1st line) - NICE TAG TA294
- Vitreomacular traction - ocriplasmin NICE TAG TA297
- Choroidal neovascularisation (pathological myopia) - ranibizumab NICE TAG TA298
- Macular oedema (central retinal vein occlusion) - aflibercept solution for injection NICE TAG TA305
- Colorectal cancer (metastatic) - aflibercept NICE TAG TA307
- Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion - NICE TAG TA409
- 11.9 Contact lenses
- 12 Ear, nose, and oropharynx
-
13 Skin
- 13.1 Management of skin conditions
- 13.2 Emollient and barrier preparations
- 13.3 Topical local anaesthetics and antipruritics
- 13.4 Topical corticosteroids
-
13.5 Preparations for eczema and psoriasis
- 13.5.1 Preparations for eczema
- 13.5.2 Preparations for psoriasis
-
13.5.3 Drugs affecting the immune response
- Atopic dermatitis (eczema) - pimecrolimus and tacrolimus - NICE TAG TA82
- Psoriasis - efalizumab and etanercept - NICE TAG TA103
- Psoriasis - infliximab - NICE TAG TA134
- Psoriasis - adalimumab - NICE TAG TA146
- Psoriasis - ustekinumab - NICE TAG TA180
- Psoriatic arthritis - etanercept, infliximab and adalimumab - NICE TAG TA199
- Psoriatic arthritis (active) - ustekinumab NICE TAG TA313
- Ustekinumab for treating active psoriatic arthritis - NICE TAG TA340
- Adalimumab for treating moderate to severe hidradenitis suppurativa - NICE TAG TA392
- Secukinumab for treating moderate to severe plaque psoriasis - NICE TAG TA350
- Apremilast for treating moderate to severe plaque psoriasis- NICE TAG TA419
- Ixekizumab for treating moderate to severe plaque psoriasis - NICE TAG TA442
- Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people - NICE TAG TA455
- Ustekinumab for moderately to severely active Crohn’s disease after previous treatment - NICE TAG TA456
- Brodalumab for treating moderate to severe plaque psoriasis - NICE TAG TA511
- Guselkumab for treating moderate to severe plaque psoriasis - NICE TAG TA521
- Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG TA537
- Dupilumab for treating moderate to severe atopic dermatitis - NICE TAG TA534
- 13.6 Acne and rosacea
- 13.7 Preparations for warts and calluses
- 13.8 Sunscreens and camouflagers
- 13.9 Shampoos and other preparations for scalp and hair conditions
- 13.10 Anti-infective skin preparations
- 13.11 Skin cleansers, antiseptics, and desloughing agents
- 13.12 Antiperspirants
- 13.13 Topical circulatory preparations
- 14 Immunological products and vaccines
-
15 Anaesthesia
-
15.1 General anaesthesia
- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative and analgesic peri-operative drugs
- 15.1.5 Neuromuscular blocking drugs
- 15.1.6 Drugs for reversal of neuromuscular blockade
- 15.1.7 Antagonists for central and respiratory depression
- 15.1.8 Drugs for malignant hyperthermia
- 15.2 Local anaesthesia
-
15.1 General anaesthesia
- Miscellaneous
-
1 Gastro-intestinal system
- New medicines / ACE
-
Guidelines
- 1. Gastro-intestinal System
- 2. Cardiovascular System Guidelines
- 3. Respiratory System Guidelines
- 4. Central Nervous System Guidelines
- 5. Infections Guidelines
- 6. Endocrine System Guidelines
- 7. Obstetrics, Gynaecology, and Urinary-tract Disorders Guidelines
- 8. Malignant Disease and Immunosuppression Guidelines
- 9. Nutrition and Blood Guidelines
- 10. Musculoskeletal and Joint Diseases Guidelines
- 11. Eye Guidelines
- 12. Ear, Nose, and Oropharynx Guidelines
- 13. Skin Guidelines
- 14. Immunological Products and Vaccines Guidelines
- 15. Anaesthesia Guidelines
-
Shared care
- 1. Gastro-intestinal System Shared Care
- 2. Cardiovascular System Shared Care
- 3. Respiratory System Shared Care
- 4. Central Nervous System Shared Care
- 5. Infections Shared Care
- 6. Endocrine System Shared Care
- 7. Obstetrics, Gynaecology, and Urinary-tract Disorders Shared Care
- 8. Malignant Disease and Immunosuppression Shared Care
- 9. Nutrition and Blood Shared Care
- 10. Musculoskeletal and Joint Diseases Shared Care
- 11. Eye Shared Care
- 12. Ear, Nose, and Oropharynx Shared Care
- 13. Skin Shared Care
- 14. Immunological Products and Vaccines Shared Care
- 15. Anaesthesia Shared Care
- Wound care
- Patient Group Directions (PGDs)
- FAQs
- Further information
- Newsletters
- Referral forms
- Self Care
- Care Homes
- High Cost Drugs
- MTRAC
- COVID-19
Ibrutinib for treating relapsed or refractory mantle cell lymphoma - NICE TAG TA502
1.1 Ibrutinib is recommended as an option for treating relapsed or refractory mantle cell lymphoma in adults, only if:
-
they have had only 1 previous line of therapy and
-
the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England.
1.2 This recommendation is not intended to affect treatment with ibrutinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.